Mineralys Therapeutics (MLYS) Times Interest Earned (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Times Interest Earned of -$0.26 for Q4 2025, up 59.61% sequentially from -$0.65 in Q4 2024, and up 59.61% YoY from -$0.16 in Q4 2024.
Mineralys Therapeutics (MLYS) Times Interest Earned (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Times Interest Earned for 4 years, with the latest figure at -$0.26 in Q4 2025.
- Quarterly Times Interest Earned rose 59.61% year-over-year to -$0.26 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.17 (up 51.56% YoY) and the FY2025 annual result came in at -$1.17, up 51.56% from the prior year.
- Times Interest Earned improved to -$0.26 in Q4 2025 per MLYS's latest filing, from -$0.65 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$0.26 in Q4 2025 and troughed at -$54.69 in Q4 2022.
- A 4-year average of -$21.98 and a median of -$16.49 in 2024 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2023 and 2024: Times Interest Earned surged 40.87% in 2023, then soared 98.0% in 2024.
- Over 4 years, Times Interest Earned stood at -$54.69 in 2022, then soared by 40.87% to -$32.33 in 2023, then jumped by 98.0% to -$0.65 in 2024, then soared by 59.61% to -$0.26 in 2025.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$0.26, -$0.65, and -$32.33 for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | -103.25 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -103.25 |
| Dec 31, 2025 | -0.26 |
| Dec 31, 2024 | -0.65 |
| Dec 31, 2023 | -32.33 |
| Dec 31, 2022 | -54.69 |